|
COVID-19 Vaccination In Mainland China
COVID-19 vaccination in mainland China is an ongoing immunization campaign against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in mainland China, in response to the ongoing pandemic in the region. As of July 2022, it is estimated that about 89.7% of the country's population has received a vaccine, and about 56% of the population has received a booster dose. __TOC__ Administration In June 2020, the Sinopharm BIBP vaccine (BBIBP-CorV) was authorized for emergency use in China. On July 22, Chinese authorities started the emergency use of COVID-19 vaccines. On December 15, 2020, the COVID-19 vaccination for people under high risk started in China. On December 19, 2020, the National Health Commission (NHC) said that there has been 1 million doses of COVID-19 vaccine administered in China as of the day, and no serious adverse reactions were observed. On December 31, 2020, NHC announced that the Sinopharm BIBP vaccine has been approved through the conditional ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
COVID-19 Pandemic In Mainland China
The COVID-19 pandemic in mainland China is part of the worldwide pandemic of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). China was the first country to experience an outbreak of the disease, the first to impose drastic measures in response (including lockdowns and face mask mandates), and one of the first countries to bring the outbreak under control. The 2019–2020 COVID-19 outbreak in mainland China was the first wave of the disease, and was first manifested as a cluster of mysterious pneumonia cases, mostly related to the Huanan Seafood Market, in Wuhan, the capital of Hubei province. It was first reported to the local government on 27 December 2019 and published on 31 December. On 8 January 2020, a new coronavirus (SARS-CoV-2) was identified as the cause of the pneumonia by Chinese scientists. By 29 January, the virus was found to have spread to all provinces of mainland China. By late February, the pand ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Inactivated Vaccine
An inactivated vaccine (or killed vaccine) is a vaccine consisting of virus particles, bacteria, or other pathogens that have been grown in culture and then killed to destroy disease-producing capacity. In contrast, live vaccines use pathogens that are still alive (but are almost always attenuated, that is, weakened). Pathogens for inactivated vaccines are grown under controlled conditions and are killed as a means to reduce infectivity and thus prevent infection from the vaccine. Inactivated vaccines were first developed in the late 1800s and early 1900s for cholera, plague, and typhoid. Today, inactivated vaccines exist for many pathogens, including influenza, polio (IPV), rabies, hepatitis A and pertussis. Because inactivated pathogens tend to produce a weaker response by the immune system than live pathogens, immunologic adjuvants and multiple "booster" injections may be required in some vaccines to provide an effective immune response against the pathogen. Attenuated vacci ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
ZF2001
ZF2001, trade-named Zifivax or ZF-UZ-VAC-2001, is an adjuvanted protein subunit COVID-19 vaccine developed by Anhui Zhifei Longcom in collaboration with the Institute of Microbiology at the Chinese Academy of Sciences. The vaccine candidate is in Phase III trials with 29,000 participants in China, Ecuador, Malaysia, Pakistan, and Uzbekistan. ZF2001 employs technology similar to other protein-based vaccines in Phase III trials from Novavax, Vector Institute, and Medicago. ZF2001 was first approved for use in Uzbekistan and later China. Production capacity is expected to be one billion doses a year in China and 200 million in Uzbekistan. By July, 100 million doses had been administered in China and Uzbekistan. Medical uses It is administered in three doses over a period of two months. Efficacy In August 2021, preliminary data from a phase III study with 28,500 participants indicated an overall efficacy of 82% against disease of any severity. Efficacy was 93% against the ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Reuters
Reuters ( ) is a news agency owned by Thomson Reuters Corporation. It employs around 2,500 journalists and 600 photojournalists in about 200 locations worldwide. Reuters is one of the largest news agencies in the world. The agency was established in London in 1851 by the German-born Paul Reuter. It was acquired by the Thomson Corporation of Canada in 2008 and now makes up the media division of Thomson Reuters. History 19th century Paul Reuter worked at a book-publishing firm in Berlin and was involved in distributing radical pamphlets at the beginning of the Revolutions in 1848. These publications brought much attention to Reuter, who in 1850 developed a prototype news service in Aachen using homing pigeons and electric telegraphy from 1851 on, in order to transmit messages between Brussels and Aachen, in what today is Aachen's Reuters House. Reuter moved to London in 1851 and established a news wire agency at the London Royal Exchange. Headquartered in London, Reuter' ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
CanSino
The Cansino family is a prominent Sephardic Jewish family originally from Oran, Algeria. The family progenitor Jacob Cansino served as an interpreter at Oran, a Spanish colony in northwestern Africa, under Charles V, until 1556, when he was sent as an ambassador to the king of Morocco. The office was then held in regular succession by his son Isaac Cansino from 1568 to 1599, by his grandson Hayyim Cansino from 1601 to 1621, and by his great-grandson Aaron Cansino from 1621 to 1633. Other prominent members of the family were Isaac ben Chayyim Cansino, poet; and Rabbi Abraham Cansino II, secretary of the Jewish community of Oran. {{JewishEncyclopedia, article=Cansino, author=Gotthard Deutsch Gotthard Deutsch (; 31 January 1859 – 14 October 1921) was a scholar of Jewish history. Education Deutsch was born in Dolní Kounice, Moravia, Austria, as Eliezer Deutsch, the son of Bernhard L. Deutsch, a merchant, and Elise Wiener. He alwa ... and A. Rhine, url=http://jewishencyc ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Viral Vector Vaccine
A viral vector vaccine is a vaccine that uses a viral vector to deliver genetic material ( DNA), which can be transcribed by the recipient's host cells as mRNA coding for a desired protein (or: antigen) to elicit an immune response. , six viral vector vaccines have been authorized for use in humans in at least one country: four COVID-19 vaccines and two Ebola vaccines. Technology Viral vector vaccines use a modified version of one virus as a vector to deliver to a cell a nucleic acid coding for an antigen for another infectious agent. Viral vector vaccines do not cause infection with either the virus used as the vector, or the source of the antigen. The genetic material it delivers does not integrate into a person's genome. Viral vector vaccines enable antigen expression within cells and induce a robust cytotoxic T cell response, unlike subunit vaccines which only confer humoral immunity. Most viral vectors are designed to be incapable of replication because the necessary gene ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Convidecia
AD5-nCOV, trade-named Convidecia, is a single-dose viral vector vaccine for COVID-19 developed by CanSino Biologics. It conducted its Phase III trials in Argentina, Chile, Mexico, Pakistan, Russia, and Saudi Arabia with 40,000 participants. In February 2021, global data from Phase III trials and 101 COVID cases showed that the intramuscular version of the vaccine had a 65.7% efficacy in preventing moderate symptoms of COVID-19, and 91% efficacy in preventing severe disease. It has similar efficacy to the Janssen vaccine, another one-shot adenovirus vector vaccine with 66% efficacy in a global trial. Convidecia is similar to other viral vector vaccines like AZD1222, Gam-COVID-Vac, and Ad26.COV2.S. Its single-dose regimen and normal refrigerator storage requirement (2° to 8 °C) could make it a favorable vaccine option for many countries. It is currently under evaluation for emergency use listing by the WHO. On May 19 2022, WHO issued EUL for the vaccine. A Phase I stu ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Chinese Academy Of Medical Sciences
Peking Union Medical College (), founded in 1906, is a selective public medical college based in Dongcheng, Beijing, China. It is a Chinese Ministry of Education Double First Class University Plan university. The school is tied to the Peking Union Medical College Hospital and has a joint 8-year clinical medicine science program with Tsinghua University. Peking Union Medical College students in the 8-year clinical medicine program could receive a Peking Union Medical College diploma and degree signed by both the Peking Union Medical College and Tsinghua presidents. It was merged with the Chinese Academy of Medical Sciences in 1957 and operates as one single institution with two names directly under the Ministry of Health, now the National Health Commission. It is the first medical school in China to introduce the 8-year M.D. program. History The Peking Union Medical College Hospital was founded in 1906. The American Board of Commissioners for Foreign Missions, the Board of F ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Chinese Academy Of Medical Sciences COVID-19 Vaccine
Chinese Academy of Medical Sciences COVID-19 vaccine, or IMBCAMS COVID-19 vaccine, traded as Covidful ( zh, s=科维福, p=Kēwéifú), is a COVID-19 vaccine A COVID19 vaccine is a vaccine intended to provide acquired immunity against severe acute respiratory syndrome coronavirus 2 (SARS‑CoV‑2), the virus that causes coronavirus disease 2019 ( COVID19). Prior to the COVID19 pandemic, an e ... developed by . Clinical trials In May 2020, Covidful started phase I/II clinical trial with 942 participants in China. In January 2021, Covidful started phase III clinical trials with 34,020 from Brazil and Malaysia. Authorizations On 9 June 2021, The vaccine has been approved by the Chinese authorities. References External links Chinese COVID-19 vaccines Inactivated vaccines {{Vaccine-stub ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Minhai COVID-19 Vaccine
Minhai COVID-19 vaccine ( zh, s=康泰民海新冠疫苗), trademarked as KCONVAC ( zh, s=可维克, p=Kěwéikè), is a COVID-19 vaccine A COVID19 vaccine is a vaccine intended to provide acquired immunity against severe acute respiratory syndrome coronavirus 2 (SARS‑CoV‑2), the virus that causes coronavirus disease 2019 ( COVID19). Prior to the COVID19 pandemic, an e ... developed by Shenzhen Kangtai Biological Products Co. Ltd and its subsidiary, Beijing Minhai Biotechnology Co., Ltd. Clinical trials In October 2020, KCONVAC started phase I clinical trials with 180 participants in China. Later, KCONVAC started phase II trials with 1,000 participants in China. In May 2021, KCONVAC started phase III trials for global trials with 28,000 participants. Children and adolescents trials In August 2021, KCONVAC started phase I trials with 84 participants in China. In September, KCONVAC started phase II trials with 480 participants in China. Authorizations On ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
National Medical Products Administration
The National Medical Products Administration (NMPA, , formerly the China Food and Drug Administration, or CFDA) was founded on the basis of the former State Food and Drug Administration (SFDA). In March 2013, the former regulatory body was rebranded and restructured as the China Food and Drug Administration, elevating it to a ministerial-level agency. In 2018, as part of China's 2018 government administration overhaul, the name was changed to 'National Medical Products Administration' and merged into the newly created State Administration for Market Regulation. The headquarters are in Xicheng District, Beijing. In its first incarnation as the CFDA, the NMPA replaced a large group of overlapping regulators with an entity similar to the Food and Drug Administration of the United States, streamlining regulation processes for food and drug safety. The National Medical Products Administration is directly under the State Council of the People's Republic of China, which is in charge of ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Sinopharm WIBP COVID-19 Vaccine
The Sinopharm WIBP COVID-19 vaccine, also known as WIBP-CorV, is one of two inactivated virus COVID-19 vaccines developed by Sinopharm. Peer-reviewed results show that the vaccine is 72.8% effective against symptomatic cases and 100% against severe cases (26 cases in vaccinated group vs. 95 cases in placebo group). The other inactivated virus COVID-19 vaccine developed by Sinopharm is the BIBP vaccine (BBIBP-CorV) which is comparably more successful. 1 billion doses are expected to be produced per year. Medical uses The vaccine is given by intramuscular injection. The administered is 2 doses in 3 weeks. Efficacy In May 2021, peer-reviewed results published in JAMA of Phase III trials in United Arab Emirates and Bahrain showed that the vaccine is 72.8% effective against symptomatic cases and 100% against severe cases (26 cases in vaccinated group vs. 95 cases in placebo group). 12,743 people received the vaccine and 12,737 people received the placebo in these trials. Manuf ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
.jpg "Click for more on -> National Medical Products Administration")